Skip to main content
Premium Trial:

Request an Annual Quote

GE to Launch New CodeLink Assay Within Two Weeks

TORONTO, Oct. 30 (GenomeWeb News) - GE Healthcare will launch its overdue 16-chamber rat ADME assay for the CodeLink platform by the middle of November, Lisa D'Anzi, marketing director for the platform, said yesterday at the American Society of Human Genetics 54th annual meeting.

 

"The assay will launch toward the end of next week or the beginning of the following," pending the completion of last-minute data, said D'Anzi. She made the remarks following a GE Healthcare-sponsored CodeLink workshop that occurred here yesterday during the ASHG meeting, held here last week.

 

BioArray News, GenomeWeb News' sister publication, reported in early June that the company originally intended to introduce the ADME-Rat 16 assay within 60 to 90 days - that is, before September.

 

The assay was to be the first produced for the CodeLink platform after GE Healthcare acquired Amersham in April. Instead, the whole mouse genome assay, which launches next week, will become the platform's first. D'Anzi said GE Healthcare was "already selling" whole mouse genome assays.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.